Skip to main content
. 2023 Apr 26;9(5):892–904. doi: 10.1021/acscentsci.3c00015

Figure 8.

Figure 8

MTDB-imi6 degrader in vivo activity against SARS-CoV-2 infection in K18-hACE2 mice. (a) Eight- to 12-week-old female K18-hACE2-transgenic mice were intranasally infected with 104 plaque-forming units (PFU) of SARS-CoV-2 and treated intranasally 1 h preinfection and 3 h postinfection with MTDB-imi6 (25 mg/kg) (n = 6), MTDB (10 mg/kg, maximal dose that could administered given limited solubility) (n = 3), TDB-imi6 (25 mg/kg) (n = 5), and vehicle control (n = 6). (b) Administration of MTDB-imi6 leads to a decrease in lung viral load of SARS-CoV-2 infected K18-hACE2 mice. No differences in lung viral load between vehicle control and MTDB and TDB-imi6-treated mice were observed. Mean ± SD is shown; *p < 0.05; unpaired t test. (c) Western blot analysis of phospho-p38 from lung extracts of transgenic K18-hACE2 mice treated with three doses of 10 mg/kg of vehicle (V1, V2) or MTDB-imi6 (D1, D2) at 1 h before infection and 1 and 2 days postinfection (n = 2).